Trial Profile

Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 11 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Aug 2022 Primary endpoint has not been met (Hazard ratio (PFS) of the nicotinamide arm to the placebo arm) , according to Results presented at the 2022 World Conference on Lung Cancer
09 Aug 2022 Results reporting OS, PFS and safety data presented at the 2022 World Conference on Lung Cancer
25 Nov 2018 Planned End Date changed from 1 Feb 2019 to 1 Jun 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com